Focus: QED Therapeutics is a small-molecule biotech focused on tyrosine kinase receptor inhibitors across neurology, rare diseases, oncology, metabolic disorders, and ophthalmology. The company is actively hiring across 69 open roles with a commercial-first organizational structure.
Profile data last refreshed 13h ago · AI intelligence enriched 1w ago
Cooling — net -16 jobs in 30d
42 added, 58 removed. Slower than typical.
Suitable for professionals seeking commercial-stage upside and rare disease expertise, but with binary clinical risk and limited research-depth opportunities.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for QED Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from QED Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles